Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada.
Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Can J Cardiol. 2017 Oct;33(10):1283-1291. doi: 10.1016/j.cjca.2017.07.012. Epub 2017 Jul 21.
Continuous flow (CF) left ventricular assist devices (LVADs) improve survival in end-stage heart failure patients who are ineligible for cardiac transplantation. Their use in this population (referred to as destination therapy) is increasing in many countries, yet they are not routinely funded for this indication in Canada. We assessed the cost-effectiveness of destination therapy CF-LVADs from the perspective of the Canadian health care payer.
A Markov model was used to project the outcomes and costs of 2 treatment pathways, CF-LVAD implantation and medical management alone, in an end-stage heart failure patient cohort ineligible for transplantation. Clinical and cost input estimates were informed from the available literature. Model outcomes included costs (in 2015 Canadian dollars), quality-adjusted life-years (QALYs), and the cost per QALY gained.
Compared with medical management, CF-LVAD patients had higher costs ($284,287 vs $31,984) and QALYs (1.48 vs 0.39) over a lifetime horizon. The incremental cost per QALY gained was $230,692. The model was most sensitive to device implantation costs, and the clinical effectiveness of CF-LVADs on survival and quality of life. A scenario analysis using contemporary survival data resulted in a cost per QALY gained of $125,936. When applying contemporary LVAD survival trends, the model showed that the cost of initial LVAD implantation needed to be less than $123,000 to be considered cost-effective.
The incremental cost per QALY for destination therapy CF-LVADs is predicted to be above usual thresholds for funding in Canada. In some plausible scenarios, its cost-effectiveness is similar to dialysis for kidney failure, a therapy that is also immediately life-saving. Because of this, there will be likely ongoing pressure to fund CF-LVADs for a subset of patients ineligible for transplantation.
连续流(CF)左心室辅助装置(LVAD)可提高不符合心脏移植条件的终末期心力衰竭患者的生存率。在许多国家,该装置在该人群中的应用(称为目的地治疗)正在增加,但在加拿大,该装置并未为此适应症提供常规资金。我们从加拿大医疗保健支付者的角度评估了目的地治疗 CF-LVAD 的成本效益。
使用马尔可夫模型来预测移植不合格的终末期心力衰竭患者队列中 CF-LVAD 植入和单独药物治疗的 2 种治疗途径的结果和成本。临床和成本投入估算来自现有文献。模型结果包括成本(以 2015 年加元计)、质量调整生命年(QALYs)和每获得一个 QALY 的成本。
与药物治疗相比,CF-LVAD 患者在终生范围内的花费更高(284287 美元对 31984 美元),QALY 更高(1.48 对 0.39)。每获得一个 QALY 的增量成本为 230692 美元。该模型对设备植入成本以及 CF-LVAD 在生存和生活质量方面的临床效果最为敏感。使用当代生存数据的情景分析得出每获得一个 QALY 的成本为 125936 美元。当应用当代 LVAD 生存趋势时,该模型表明初始 LVAD 植入的成本需要低于 123000 美元才能被认为具有成本效益。
目的地治疗 CF-LVAD 的每 QALY 增量成本预计将高于加拿大的资金通常阈值。在某些合理的情况下,其成本效益与肾衰竭的透析相似,而透析是一种立即救命的疗法。因此,对于不符合移植条件的一部分患者,可能会继续面临为 CF-LVAD 提供资金的压力。